Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
Fragile X Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Scientific Presentations
Publications
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2024
2023
2022
2021
2020
2019
2018
2017
Older
Dec 29, 2017
Final Director's Interest Notice
Dec 29, 2017
Non-executive director retirement
Dec 27, 2017
Change in substantial holding
Dec 05, 2017
Neuren announces new US patent to be granted for NNZ-2591
Nov 16, 2017
Consolidation/Split - NEU
Nov 16, 2017
Notification under Listing Rule 7.20 of share reorganisation
Oct 26, 2017
Appendix 4C - quarterly
Oct 13, 2017
Neuren FDA meeting confirms Phase 3 plan for Rett syndrome
Oct 06, 2017
Investor presentation, 6 October 2017
Oct 05, 2017
Presentations and publication for Rett syndrome trials
1
2
3
4
5
Next
